Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Yonsei Medical Journal|August 28, 2024
Exploring the Expression and Function of T Cell Surface Markers Identified through Cellular Indexing of Transcriptomes and Epitopes by SequencingJoon Yeon Hwang, Youngtaek Kim, Kwangmin Na, et al.
Yonsei Medical Journal|November 28, 2024
Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster AnalysisYoungtaek Kim, Joon Yeon Hwang, Kwangmin Na, et al.
Cancers|September 28, 2023
Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic StrategiesYoungtaek Kim, Joon Yeon Hwang, Dong Kwon Kim, et al.
Yonsei Medical Journal|December 16, 2021
Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin TumorChun-Bong Synn, Dong Kwon Kim, Jae Hwan Kim, et al.
Frontiers in Immunology|April 29, 2024
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer typesDong Kwon Kim, Chai Young Lee, Yu Jin Han, et al.
Frontiers in Immunology|March 22, 2024
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine productionKwangmin Na, Seul Lee, Dong Kwon Kim, et al.
Journal for Immunotherapy of Cancer|May 15, 2026
Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanomaJii Bum Lee, Sujeong Baek, Dong Kwon Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Frontiers in Chemistry|December 22, 2022
YH29407 with anti-PD-1 ameliorates anti-tumor effects <i>via</i> increased T cell functionality and antigen presenting machinery in the tumor microenvironmentDong Kwon Kim, Chun-Bong Synn, Seung Min Yang, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Pageof 3